Pharmaceutical

Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology

WEXFORD, Pa. and PRINCETON, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SNAP Biosciences, Inc a majority-owned subsidiary of Coeptis Therapeutics...

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

NEEDHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical...

Real World Evidence (RWE) Oncology Market to Reach $3.51 Billion by 2035, Growing at a CAGR of 14.7% from 2025–Exclusive Report by Meticulous Research®

Market Growth Driven by Increasing Demand for Real-World Evidence in Drug Development, Rising Focus on Value-Based Healthcare, Growing Cancer Incidence...

QI Path Launches AI-driven Risk Intelligence Platform To Transform Risk Mitigation and Regulatory Readiness Across the Drug Development Lifecycle

BOULDER, Colo., May 27, 2025 /PRNewswire/ -- In response to the mounting regulatory, operational, and reputational pressures facing pharmaceutical companies and...

MOBILion Systems to Highlight Customer Use Cases from its MOBIE® Platform and Unveil Plans for their Next Generation Proteomics Platform at ASMS 2025

CHADDS FORD, Pa., May 27, 2025 /PRNewswire/ -- MOBILion Systems, Inc., a leader in separation science innovation, will attend and...

STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evaluate STC-15 in Combination with LOQTORZI® and Appointment of Atif Abbas, M.D., as Chief Medical Officer

STC-15 has demonstrated durable clinical activity and tolerability to progress into a combination study with a checkpoint inhibitor  Collaboration enables...

AskBio Announces Publication of Complete Results of Phase 1b Trial of AB-1005 Gene Therapy in Participants with Parkinson’s Disease in Movement Disorders

Research Triangle Park, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- AB-1005 was well tolerated with no attributed serious adverse events...

error: Content is protected !!